Insulin Resistance as a Disease of Civilization
DOI:
https://doi.org/10.12775/mbs-2013-0030Keywords
insulin resistance, obesity, carbohydrate metabolism disordersAbstract
Civilization - related diseases can be defined as those caused by the effects of harmful factors resulting from the development of civilization, the progressive industrialization and changes in lifestyle that derive from the use of achievements of modern civilization. Abdominal obesity and diabetes are the most typical examples of such ailments.
Insulin resistance underpins the obesity and type 2 diabetes’ twin epidemics and explains many of the metabolic problems that, linked together, are called a metabolic syndrome. It is defined as a glucose homeostasis disorder, in terms of reduced sensitivity of muscle, fat, liver and other body tissues to insulin. There are three possible mechanisms of insulin resistance: pre-receptor, receptor and post-receptor.
Insulin resistance may not be the only and the basic problem of the patient directly leading to impaired glucose metabolism in the form of diabetes. It may be an additional issue, related to another disease the patient is suffering from, and leading to serious complications, including diabetes. This is due to a variety of hormonal disorders occurring in various diseases and leading to the emergence of resistance to insulin.
Most of the hormones diminish the effect of insulin in the body in the mechanism of action of the liver and the peripheral tissues. The hormones that in excess most often cause carbohydrate metabolism disorders include growth hormone, thyroxine, glucocorticoids, catecholamine, parathyroid hormone, aldosterone, glucagon and somatostatin. The effect of their activity is hyperinsulinemia resulting from the compensatory rise in insulin secretion in response to increasing insulin resistance.
The awareness of insulin resistance prevalence in different globally widely spread disease entities and the understanding of the mechanisms leading to it should contribute to taking better care of patients originally being treated because of other reasons.
References
Stears A, O'Rahilly S, Semple RK, Savage DB. Metabolic insights from extreme human insulin resistance phenotypes. Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, University of Cambridge, UK. Best Pract Res Clin Endocrinol Metab 2012; 26:145-157.[http://dx.doi.org/10.1016/j.beem.2011.09.003]
Yudkin JS: Insulin resistance and the metabolic syndrome or the pitfalls of epidemiology. Diabetologia 2007; 50: 1576-1586.[ http://dx.doi.org/10.1007/s00125-007-0711-3]
Szurkowska M, Szafraniec K, Gilis-Janiuszewska A, et al. Wskaźniki insulinooporności w badaniu populacyjnym i ich wartość predykcyjna w określeniu zespołu metabolicznego. Przegląd epidemiologiczny 2005; 59: 743-751.
Krassowski J: Tolerancja glukozy w endokrynopatiach. Diabetologia Praktyczna 2004; 5: 51-55.
Behceci M, Tuzcu A, Behceci S, Tuzcu S. Is hyperprolactinemia associated with insulin resistance in non-obese patients with policystic ovary syndrome? Endocrinol Invest 2003; 26: 655-659.
Grzesiuk W, Szydlarska D, Jóźwik K. Insulinooporność w endokrynopatiach. Endokrynologia, Otyłość i Zaburzenia Przemiany Materii 2008; 5: 38-44.
Donckier JE: Endocrine diseases and diabetes. W: Pickup J.C., Williams G. red. Textbook of diabetes. Blackwell Publishing 2003; 27.1-27.15.
Tamer G, Mert M, Tamer I, Mesci B, Kilic D, Arik S. Effects of thyroid autoimmunity on abdominal obesity and hyperlipidaemia. Pol J Endocrinol 2011; 62: 421-428.
Gierach M, Gierach J, Skowrońska A, Rutkowska E, Spychalska M, Pujanek M, Junik R. Hashimoto’s thyroiditis and carbohydrate metabolism disorders in patients hospitalised in the Department of Endocrinology and Diabetology of Ludwik Rydygier Collegium Medicum in Bydgoszcz between 2001 and 2010. Pol J Endocrinol 2012; 63: 14-17.
Midoricawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T. The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin Endocrinol 2001; 54: 797-804.
[http://dx.doi.org/10.1046/j.1365-2265.2001.01274.x]
Otto-Buczkowska E: Cukrzyca wtórna. Medycyna Metaboliczna 2003; 7: 49-56.
Bączyk M, Ziemnicka K, Bączyk E, Łuczak Jacek. Zaburzenia regulacji glikemii u osób z zaawansowaną chorobą nowotworową. Polska Medycyna Paliatywna 2002; 1: 49-55.
Gnacińska M, Małgorzewicz S, Guzek M, Łysiak- Szydłowska W, Dworczak K. Adipose tissue activity in relation to overweight or obesity. Pol J Endocrinol 2010; 61: 160-168.
Jankiewicz-Wika J, Kołomecki K, Cywiński J et al. Impact of vertical banded gastroplasty on body weight, insulin resistance, adipocytokine, inflammation and metabolic syndrome markers in morbidly obese patients. Pol J Endocrinol 2011; 62: 109-119.
Garanty-Bogacka B, Syrenicz M, Goral J et al. Changes in inflammatory biomarkers after successfull life style intervention in obese children. Pol J Endocrinol 2011; 62: 499-505.
Radenković SP, Kocić RD, Pešić MM et al. The hypertriglyceridemic waist phenotype and metabolic syndrome by differing criteria in type 2 diabetic patients and their relation to lipids and blood glucose control. Pol J Endocrinol 2011; 62: 316-323.
Chiżyński K: Czy insulinoopornść jest czynnikiem ryzyka choroby niedokrwiennej serca? Polski Przegląd Kardiologiczny 2002; 4: 331-335.
Lim S, Park YM, Sakuma I, Koh KK. How to control residual cardiovascular risk despite statin treatment: Focusing on HDL-cholesterol. Int J Cardiol 2012; 12: 14-16.
Zachurzok-Buczyńska A, Klimek K, Firek-Pedras M, Małecka-Tendera E. Are metabolic syndrome and its components in obese children influenced by the overweight status or the insulin resistance? Pol J Endocrinol 2011; 62: 102-108.
Downloads
Published
How to Cite
Issue
Section
Stats
Number of views and downloads: 295
Number of citations: 0